{"id":2310,"date":"2017-09-12T00:00:00","date_gmt":"2017-09-12T00:00:00","guid":{"rendered":"http:\/\/www.pharma-mkting.comindex.php\/2017\/09\/12\/pinup091217\/"},"modified":"2019-02-06T02:14:49","modified_gmt":"2019-02-06T02:14:49","slug":"pinup091217","status":"publish","type":"post","link":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/articles\/news\/pinup091217\/","title":{"rendered":"PinUp: Fueling the opioid epidemic, Failure to report deaths due to EpiPen, Facebook clinical trail advertising failure"},"content":{"rendered":"

Pharma Industry News Update<\/b>: 12 Sept 2017<\/p>\n\n

Insys Therapeutics’ Sales Strategy Fueled the Opioid Epidemic<\/p>\n


A “Key Strategic Imperative”<\/b><\/p>\n

[From www.statnews.com] In early 2015, an Insys Therapeutics employee called an insurer and provided misleading patient information in order to win clearance for a prescription for its Subsys painkiller. The conversation – in which the employee pretended to call from a physician’s office – was about a woman named Sarah Fuller, whose family later claimed she died because she was inappropriately prescribed the drug.<\/p>\n

The phone call was made scarcely a year after a consultant warned the drug maker that it lacked needed policies for governing such activities, but Insys executives failed to take corrective action, according to U.S. Sen. Claire McCaskill (D-Mo.), who released a copy of the consultant’s report and a recording of the phone call as part of an ongoing investigation into the opioid crisis (see report here<\/a>).<\/p>\n

The details of both the phone call and the report help flesh out what is already a disturbing picture of unchecked pharmaceutical marketing.<\/p>\n

More…<\/a><\/p>\n

Further Reading:<\/b><\/p>\n